- TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures
- 100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients
- 64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients
- 80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposures
- Favorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse events
Trade with Eva: Analytics in action >>
Thursday, December 5, 2024
===Protara Therapeutics (TARA) : Positive results from Phase 2 ADVANCED-2 trial of TARA-002 in patients with NMIBC
Labels:
PRINTAA,
TARA,
type X check
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment